InsidersTradesSigma
Genmab A/S Stock: price and directors' dealings · Denmark · Finanstilsynet DK
Follow the Genmab A/S share price and the full management transaction log of the company, a publicly traded company based in Denmark. Shares are quoted on DK DK, under the oversight of Finanstilsynet DK. Operating in the Health Care sector, Genmab A/S has published 141 reports. Market capitalisation: €116.4bn. The latest transaction was reported on 29 May 2026 (Sale). Among the most active insiders: Unknown. All data is free.
141
Insider Decl.
0
Thresholds
€9m
16 ops.
Buy Volume
€33m
26 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Genmab A/S Buy (bullish), based on 15 analysts. Average price target: DKK 2,334.74.
10Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 10,714 of 26,334 companies
56.7
score / 100
Value41
Quality73
FCF yld1.0%
Earn yld0.8%
EV/EBITDA·
ROE15%
Gross mgn94%
Net mgn26%
Debt/EBITDA4.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 29 May 2026
Declarations141 total
221 shares@ DKK 1,734.750.0000% mcap100.0% of flowShareXCSEDK:1445447
8,525 shares@ DKK 1,758.500.0016% mcap4.6% of flowShareOutside the marketDK:1430992
6 shares@ DKK 1.800.0% of flowShareOutside the marketDK:1423836
567 shares0ShareOutside the marketDK:1423824
33,293 shares0ShareOutside the marketDK:1423440
899 shares@ DKK 1,810.000.0002% mcap0.5% of flowShareXCSEDK:1421715
378 shares@ DKK 2,043.000.0001% mcap0.2% of flowShareOutside a market placeDK:1403941
42 shares@ DKK 1,960.500.0000% mcap0.0% of flowShareAQEUDK:1401641
23,266 shares@ DKK 1,025.000.0026% mcap7.3% of flowShareOutside the marketDK:1387733
24 shares@ DKK 1,485.000.0000% mcap0.0% of flowShareXCSEDK:1371150
996 shares0ShareOutside a market placeDK:1352989
1,311 shares0ShareOutside the marketDK:1348625
5,078 shares0ShareOutside a market placeDK:1346934
36,373 shares0ShareOutside the marketDK:1346363
454 shares0ShareOutside a market placeDK:1331369
24,461 shares@ DKK 1,032.000.0027% mcap7.7% of flowShareOutside the marketDK:1310577
6 shares@ DKK 1,914.000.0000% mcap0.0% of flowShareAQEUDK:1301181
837 shares0ShareOutside the marketDK:1280998
7,000 shares@ DKK 27.78810.0000% mcap0.1% of flowShareXNASDK:1279104
Ideal exit: 24 Nov 2024 (T+270)
5,630 shares0ShareOutside a market placeDK:1278822
11,299 shares@ DKK 1,942.860.0024% mcap6.7% of flowShareAquis Exchange (AQEA, AQED, AQEU)DK:1278470
5,147 shares@ DKK 1,025.000.0006% mcap1.6% of flowShareOutside the marketDK:1277786
27,404 shares0ShareOutside the marketDK:1277173
335 shares0ShareOutside a market placeDK:1267553
559 shares0ShareOutside the marketDK:1260557
25 of 141 declarations
About Genmab A/S
Genmab A/S is a Danish biopharmaceutical company focused on developing therapeutic antibodies for cancer treatment. It is listed on the Copenhagen Stock Exchange.
